| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 204 | 2023 | 1533 | 27.590 |
Why?
|
| Antihypertensive Agents | 74 | 2023 | 497 | 14.580 |
Why?
|
| Blood Pressure | 113 | 2023 | 1449 | 10.030 |
Why?
|
| Cardiovascular Diseases | 44 | 2020 | 938 | 5.410 |
Why?
|
| Nutrition Surveys | 21 | 2022 | 204 | 3.800 |
Why?
|
| Prehypertension | 9 | 2017 | 40 | 3.050 |
Why?
|
| Obesity | 40 | 2021 | 1074 | 2.900 |
Why?
|
| Humans | 296 | 2023 | 68549 | 2.810 |
Why?
|
| Primary Health Care | 18 | 2021 | 702 | 2.810 |
Why?
|
| Blood Pressure Determination | 20 | 2022 | 151 | 2.560 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2017 | 212 | 2.480 |
Why?
|
| Middle Aged | 143 | 2021 | 21119 | 2.430 |
Why?
|
| Male | 190 | 2022 | 37283 | 2.330 |
Why?
|
| Practice Guidelines as Topic | 15 | 2021 | 772 | 2.290 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2021 | 189 | 2.240 |
Why?
|
| Risk Factors | 73 | 2020 | 5720 | 2.240 |
Why?
|
| Diet, Sodium-Restricted | 18 | 2010 | 45 | 2.220 |
Why?
|
| Life Style | 19 | 2020 | 338 | 2.210 |
Why?
|
| Adult | 142 | 2022 | 21379 | 2.190 |
Why?
|
| Female | 166 | 2022 | 38021 | 2.170 |
Why?
|
| Cholesterol | 8 | 2020 | 331 | 1.960 |
Why?
|
| Aged | 80 | 2022 | 14842 | 1.940 |
Why?
|
| Diabetes Mellitus | 11 | 2021 | 694 | 1.910 |
Why?
|
| Prevalence | 28 | 2021 | 1609 | 1.860 |
Why?
|
| United States | 49 | 2022 | 7338 | 1.860 |
Why?
|
| Hypercholesterolemia | 6 | 2017 | 86 | 1.850 |
Why?
|
| Metabolic Syndrome | 11 | 2015 | 191 | 1.750 |
Why?
|
| Drug Resistance | 8 | 2016 | 223 | 1.700 |
Why?
|
| Health Promotion | 10 | 2015 | 407 | 1.680 |
Why?
|
| Fatty Acids, Nonesterified | 17 | 2006 | 48 | 1.540 |
Why?
|
| Blood Glucose | 13 | 2020 | 631 | 1.540 |
Why?
|
| Cholesterol, LDL | 9 | 2017 | 161 | 1.450 |
Why?
|
| Community Health Services | 6 | 2014 | 141 | 1.400 |
Why?
|
| Renin | 17 | 2016 | 96 | 1.300 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2021 | 201 | 1.280 |
Why?
|
| Anticholesteremic Agents | 3 | 2017 | 49 | 1.270 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 503 | 1.230 |
Why?
|
| Heart Rate | 21 | 2021 | 568 | 1.230 |
Why?
|
| Insulin | 21 | 2012 | 617 | 1.190 |
Why?
|
| Insulin Resistance | 16 | 2014 | 241 | 1.180 |
Why?
|
| Diuretics | 11 | 2022 | 96 | 1.160 |
Why?
|
| Exercise | 7 | 2021 | 658 | 1.150 |
Why?
|
| Hyperlipidemias | 10 | 2006 | 90 | 1.130 |
Why?
|
| Medication Adherence | 6 | 2022 | 335 | 1.120 |
Why?
|
| Community Networks | 4 | 2014 | 96 | 1.120 |
Why?
|
| Sympathetic Nervous System | 7 | 2006 | 81 | 1.100 |
Why?
|
| Insurance, Health | 3 | 2017 | 200 | 1.090 |
Why?
|
| Atherosclerosis | 3 | 2017 | 204 | 1.080 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2016 | 25 | 1.020 |
Why?
|
| Disease Management | 4 | 2018 | 248 | 1.010 |
Why?
|
| Kidney | 4 | 2021 | 945 | 1.000 |
Why?
|
| Diet | 7 | 2020 | 514 | 0.990 |
Why?
|
| Age Distribution | 7 | 2020 | 319 | 0.990 |
Why?
|
| Endothelium, Vascular | 6 | 2013 | 371 | 0.980 |
Why?
|
| Body Mass Index | 22 | 2020 | 866 | 0.970 |
Why?
|
| Muscle, Smooth, Vascular | 9 | 2001 | 317 | 0.950 |
Why?
|
| Sodium Chloride, Dietary | 5 | 2009 | 50 | 0.950 |
Why?
|
| Young Adult | 18 | 2021 | 5710 | 0.910 |
Why?
|
| Receptors, Adrenergic, alpha | 10 | 1998 | 40 | 0.890 |
Why?
|
| Renin-Angiotensin System | 7 | 2013 | 78 | 0.880 |
Why?
|
| Sex Distribution | 5 | 2020 | 272 | 0.880 |
Why?
|
| Kidney Diseases | 3 | 2019 | 307 | 0.830 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2021 | 8 | 0.810 |
Why?
|
| Fat Emulsions, Intravenous | 10 | 2004 | 18 | 0.810 |
Why?
|
| Health Equity | 2 | 2020 | 15 | 0.790 |
Why?
|
| Age Factors | 17 | 2020 | 1860 | 0.790 |
Why?
|
| Goals | 4 | 2020 | 65 | 0.790 |
Why?
|
| Tetrazoles | 9 | 2014 | 160 | 0.790 |
Why?
|
| Weight Loss | 5 | 2021 | 319 | 0.780 |
Why?
|
| Societies, Medical | 4 | 2015 | 403 | 0.770 |
Why?
|
| Lipids | 6 | 2013 | 298 | 0.770 |
Why?
|
| Hydrochlorothiazide | 5 | 2013 | 15 | 0.760 |
Why?
|
| Multivariate Analysis | 12 | 2016 | 1046 | 0.750 |
Why?
|
| Fatty Acids | 8 | 2021 | 222 | 0.750 |
Why?
|
| Physicians, Primary Care | 2 | 2018 | 46 | 0.710 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2018 | 41 | 0.710 |
Why?
|
| Dietary Proteins | 1 | 2020 | 51 | 0.710 |
Why?
|
| Sympathectomy | 3 | 2021 | 24 | 0.700 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 8 | 2014 | 95 | 0.700 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 4843 | 0.690 |
Why?
|
| Patient Care | 2 | 2018 | 61 | 0.690 |
Why?
|
| Multiple Chronic Conditions | 1 | 2019 | 9 | 0.690 |
Why?
|
| Guideline Adherence | 4 | 2019 | 285 | 0.680 |
Why?
|
| Vascular Resistance | 18 | 2009 | 179 | 0.680 |
Why?
|
| Hemodynamics | 19 | 2021 | 705 | 0.670 |
Why?
|
| Quality Improvement | 4 | 2018 | 413 | 0.660 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2011 | 142 | 0.660 |
Why?
|
| Hypotension | 2 | 2016 | 74 | 0.660 |
Why?
|
| Cardiologists | 1 | 2018 | 9 | 0.650 |
Why?
|
| South Carolina | 20 | 2020 | 2752 | 0.650 |
Why?
|
| Cardiology | 3 | 2019 | 140 | 0.640 |
Why?
|
| Oleic Acid | 6 | 2001 | 40 | 0.630 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 7 | 2022 | 89 | 0.630 |
Why?
|
| Baroreflex | 3 | 2006 | 20 | 0.630 |
Why?
|
| Whey Proteins | 1 | 2018 | 8 | 0.620 |
Why?
|
| Ambulatory Care | 2 | 2020 | 339 | 0.620 |
Why?
|
| Treatment Outcome | 24 | 2020 | 7028 | 0.620 |
Why?
|
| Primary Prevention | 3 | 2018 | 115 | 0.620 |
Why?
|
| Medical Assistance | 1 | 2017 | 9 | 0.610 |
Why?
|
| Private Sector | 1 | 2017 | 18 | 0.610 |
Why?
|
| Medically Uninsured | 2 | 2017 | 99 | 0.610 |
Why?
|
| Medicare | 2 | 2019 | 316 | 0.600 |
Why?
|
| Military Personnel | 1 | 2020 | 221 | 0.600 |
Why?
|
| Insurance Coverage | 2 | 2017 | 99 | 0.590 |
Why?
|
| Systole | 7 | 2019 | 149 | 0.590 |
Why?
|
| Specialization | 2 | 2014 | 66 | 0.580 |
Why?
|
| Heart Diseases | 3 | 2016 | 276 | 0.570 |
Why?
|
| Disease Progression | 8 | 2013 | 1037 | 0.570 |
Why?
|
| Anti-Obesity Agents | 2 | 2021 | 42 | 0.560 |
Why?
|
| Vasoconstriction | 9 | 1997 | 81 | 0.560 |
Why?
|
| Veins | 6 | 2001 | 68 | 0.560 |
Why?
|
| Logistic Models | 12 | 2016 | 1419 | 0.560 |
Why?
|
| Environment Design | 2 | 2015 | 40 | 0.560 |
Why?
|
| Behavior Therapy | 2 | 2020 | 297 | 0.550 |
Why?
|
| Ischemic Attack, Transient | 5 | 2022 | 167 | 0.550 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 32 | 0.550 |
Why?
|
| Cognition | 2 | 2018 | 512 | 0.550 |
Why?
|
| Angiotensin II | 9 | 2001 | 220 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 1085 | 0.540 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 2 | 2006 | 12 | 0.530 |
Why?
|
| Telephone | 2 | 2014 | 160 | 0.520 |
Why?
|
| Comorbidity | 8 | 2016 | 1425 | 0.520 |
Why?
|
| Pressoreceptors | 7 | 2004 | 15 | 0.510 |
Why?
|
| Smoking Cessation | 3 | 2020 | 1032 | 0.510 |
Why?
|
| Aldosterone | 8 | 2010 | 51 | 0.510 |
Why?
|
| Benzimidazoles | 6 | 2014 | 128 | 0.500 |
Why?
|
| Phenylephrine | 12 | 2006 | 61 | 0.500 |
Why?
|
| Adolescent | 21 | 2021 | 8904 | 0.500 |
Why?
|
| Risk Assessment | 6 | 2015 | 2004 | 0.500 |
Why?
|
| Directive Counseling | 1 | 2014 | 23 | 0.490 |
Why?
|
| Oxidative Stress | 4 | 2009 | 718 | 0.490 |
Why?
|
| Hand | 4 | 2001 | 90 | 0.490 |
Why?
|
| Retrospective Studies | 18 | 2022 | 7268 | 0.490 |
Why?
|
| Residence Characteristics | 3 | 2013 | 252 | 0.480 |
Why?
|
| Biomarkers | 15 | 2017 | 1593 | 0.470 |
Why?
|
| Stroke | 12 | 2022 | 2162 | 0.470 |
Why?
|
| Medically Underserved Area | 4 | 2018 | 85 | 0.460 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 93 | 0.460 |
Why?
|
| Hypolipidemic Agents | 4 | 2017 | 82 | 0.460 |
Why?
|
| Awareness | 2 | 2012 | 81 | 0.460 |
Why?
|
| Hypertension, Renal | 1 | 2013 | 29 | 0.460 |
Why?
|
| Calcium Channel Blockers | 5 | 2022 | 137 | 0.460 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 378 | 0.460 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2013 | 38 | 0.460 |
Why?
|
| Comparative Effectiveness Research | 2 | 2013 | 36 | 0.460 |
Why?
|
| Cross-Sectional Studies | 11 | 2019 | 2265 | 0.450 |
Why?
|
| Precision Medicine | 1 | 2014 | 111 | 0.450 |
Why?
|
| Public Health | 2 | 2014 | 201 | 0.450 |
Why?
|
| Diglycerides | 1 | 2013 | 49 | 0.450 |
Why?
|
| Sodium, Dietary | 5 | 2009 | 31 | 0.450 |
Why?
|
| Mexican Americans | 1 | 2013 | 30 | 0.450 |
Why?
|
| Data Mining | 1 | 2013 | 45 | 0.450 |
Why?
|
| Vitamin D | 1 | 2018 | 516 | 0.450 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.440 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 225 | 0.440 |
Why?
|
| Triglycerides | 6 | 2006 | 184 | 0.440 |
Why?
|
| Pilot Projects | 7 | 2021 | 1341 | 0.430 |
Why?
|
| Leadership | 1 | 2014 | 136 | 0.430 |
Why?
|
| American Heart Association | 5 | 2021 | 142 | 0.430 |
Why?
|
| Program Development | 1 | 2014 | 240 | 0.430 |
Why?
|
| Patient Care Team | 2 | 2014 | 311 | 0.430 |
Why?
|
| Veterans | 1 | 2020 | 904 | 0.430 |
Why?
|
| Adrenergic alpha-Agonists | 5 | 2006 | 57 | 0.430 |
Why?
|
| Southeastern United States | 11 | 2012 | 281 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2016 | 1745 | 0.420 |
Why?
|
| Oleic Acids | 5 | 2004 | 40 | 0.420 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 102 | 0.420 |
Why?
|
| Time Factors | 16 | 2020 | 4655 | 0.420 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 186 | 0.410 |
Why?
|
| Sodium Chloride | 7 | 2009 | 136 | 0.410 |
Why?
|
| Drug Utilization | 2 | 2010 | 119 | 0.410 |
Why?
|
| Waist-Hip Ratio | 2 | 2008 | 14 | 0.390 |
Why?
|
| Fluid Shifts | 1 | 2010 | 2 | 0.380 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 370 | 0.380 |
Why?
|
| C-Reactive Protein | 9 | 2013 | 180 | 0.380 |
Why?
|
| Heart Failure | 3 | 2019 | 1179 | 0.370 |
Why?
|
| Christianity | 2 | 2001 | 16 | 0.370 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2008 | 40 | 0.370 |
Why?
|
| F2-Isoprostanes | 4 | 2009 | 14 | 0.370 |
Why?
|
| Double-Blind Method | 14 | 2018 | 1738 | 0.370 |
Why?
|
| Candy | 1 | 2010 | 3 | 0.370 |
Why?
|
| Diabetes Complications | 7 | 2013 | 249 | 0.360 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2022 | 373 | 0.360 |
Why?
|
| Cacao | 1 | 2010 | 11 | 0.360 |
Why?
|
| Physician's Role | 2 | 2013 | 116 | 0.360 |
Why?
|
| Clinical Trials as Topic | 7 | 2014 | 848 | 0.350 |
Why?
|
| Incidence | 8 | 2018 | 1582 | 0.350 |
Why?
|
| Potassium Chloride | 1 | 2009 | 45 | 0.340 |
Why?
|
| Norepinephrine | 10 | 2021 | 276 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2001 | 250 | 0.340 |
Why?
|
| Sleep | 1 | 2011 | 263 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2013 | 766 | 0.330 |
Why?
|
| Protein Kinase C | 4 | 2001 | 270 | 0.330 |
Why?
|
| Phenols | 1 | 2009 | 73 | 0.330 |
Why?
|
| Drug Combinations | 4 | 2022 | 304 | 0.330 |
Why?
|
| Feeding Behavior | 3 | 2020 | 224 | 0.320 |
Why?
|
| Albuminuria | 1 | 2009 | 171 | 0.320 |
Why?
|
| Blood Vessels | 5 | 1996 | 102 | 0.320 |
Why?
|
| Education, Medical, Continuing | 4 | 2011 | 136 | 0.320 |
Why?
|
| Angina Pectoris | 2 | 2005 | 61 | 0.320 |
Why?
|
| Hospitalization | 5 | 2015 | 977 | 0.320 |
Why?
|
| Drug Therapy, Combination | 8 | 2012 | 648 | 0.310 |
Why?
|
| Health Care Costs | 4 | 2019 | 346 | 0.310 |
Why?
|
| Body Weight | 6 | 2007 | 554 | 0.310 |
Why?
|
| Blood Platelets | 5 | 2022 | 284 | 0.310 |
Why?
|
| Dietary Fiber | 5 | 2009 | 37 | 0.310 |
Why?
|
| Plant Extracts | 1 | 2009 | 122 | 0.310 |
Why?
|
| Losartan | 2 | 2004 | 45 | 0.310 |
Why?
|
| Health Services Accessibility | 7 | 2018 | 581 | 0.310 |
Why?
|
| Sodium | 5 | 2014 | 161 | 0.310 |
Why?
|
| Potassium | 6 | 2012 | 168 | 0.300 |
Why?
|
| Platelet Count | 3 | 2013 | 100 | 0.300 |
Why?
|
| Socioeconomic Factors | 8 | 2013 | 955 | 0.300 |
Why?
|
| Leukocyte Count | 2 | 2014 | 94 | 0.300 |
Why?
|
| Regional Blood Flow | 9 | 2013 | 168 | 0.290 |
Why?
|
| Valine | 3 | 2012 | 43 | 0.290 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 696 | 0.290 |
Why?
|
| Database Management Systems | 2 | 2004 | 25 | 0.290 |
Why?
|
| Research Design | 6 | 2012 | 729 | 0.290 |
Why?
|
| Body Height | 2 | 2007 | 67 | 0.290 |
Why?
|
| Mass Screening | 2 | 2010 | 838 | 0.290 |
Why?
|
| Microcirculation | 2 | 2001 | 77 | 0.290 |
Why?
|
| Heparin | 8 | 2003 | 205 | 0.290 |
Why?
|
| Intracranial Embolism | 2 | 2019 | 25 | 0.280 |
Why?
|
| Coronary Disease | 4 | 2005 | 358 | 0.280 |
Why?
|
| Surveys and Questionnaires | 7 | 2018 | 2798 | 0.280 |
Why?
|
| Health Behavior | 4 | 2017 | 458 | 0.270 |
Why?
|
| Forearm | 9 | 1995 | 25 | 0.270 |
Why?
|
| Body Image | 1 | 2007 | 100 | 0.270 |
Why?
|
| von Willebrand Factor | 2 | 2017 | 47 | 0.260 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 81 | 0.260 |
Why?
|
| Income | 2 | 2020 | 165 | 0.260 |
Why?
|
| Risk Adjustment | 2 | 2016 | 49 | 0.260 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2004 | 155 | 0.260 |
Why?
|
| Protein Precursors | 2 | 2017 | 105 | 0.260 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2022 | 140 | 0.260 |
Why?
|
| Carotid Stenosis | 2 | 2019 | 163 | 0.260 |
Why?
|
| Dyslipidemias | 2 | 2006 | 98 | 0.260 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 71 | 0.250 |
Why?
|
| Aspirin | 4 | 2022 | 295 | 0.250 |
Why?
|
| Cohort Studies | 11 | 2014 | 2356 | 0.250 |
Why?
|
| Animals | 21 | 2013 | 20880 | 0.250 |
Why?
|
| Poverty | 4 | 2017 | 218 | 0.250 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 3256 | 0.250 |
Why?
|
| Blood Volume | 5 | 2010 | 47 | 0.240 |
Why?
|
| Chest Pain | 1 | 2005 | 151 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 929 | 0.240 |
Why?
|
| Sex Factors | 7 | 2012 | 1265 | 0.240 |
Why?
|
| Receptors, Angiotensin | 1 | 2004 | 59 | 0.240 |
Why?
|
| Treatment Failure | 2 | 2016 | 216 | 0.240 |
Why?
|
| Metoprolol | 2 | 2018 | 8 | 0.230 |
Why?
|
| Indomethacin | 3 | 2001 | 107 | 0.230 |
Why?
|
| Cholesterol, HDL | 5 | 2005 | 112 | 0.230 |
Why?
|
| Vasodilation | 3 | 2018 | 85 | 0.230 |
Why?
|
| Public Health Practice | 1 | 2003 | 23 | 0.230 |
Why?
|
| Proportional Hazards Models | 5 | 2012 | 791 | 0.230 |
Why?
|
| Medical History Taking | 2 | 2022 | 94 | 0.230 |
Why?
|
| Niacin | 1 | 2003 | 12 | 0.220 |
Why?
|
| White Coat Hypertension | 1 | 2022 | 4 | 0.220 |
Why?
|
| Emergency Shelter | 1 | 2022 | 4 | 0.220 |
Why?
|
| Prospective Studies | 10 | 2022 | 3703 | 0.220 |
Why?
|
| Tablets | 1 | 2022 | 19 | 0.220 |
Why?
|
| Masked Hypertension | 1 | 2022 | 7 | 0.220 |
Why?
|
| Quality of Health Care | 1 | 2006 | 322 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2001 | 2689 | 0.220 |
Why?
|
| Diastole | 5 | 2006 | 161 | 0.220 |
Why?
|
| Spironolactone | 2 | 2014 | 13 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 7 | 2013 | 365 | 0.210 |
Why?
|
| Hypokalemia | 1 | 2002 | 12 | 0.210 |
Why?
|
| Biphenyl Compounds | 6 | 2014 | 184 | 0.210 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 12 | 0.210 |
Why?
|
| Cluster Analysis | 7 | 2013 | 219 | 0.210 |
Why?
|
| Circadian Rhythm | 4 | 2023 | 218 | 0.200 |
Why?
|
| Population Surveillance | 1 | 2004 | 285 | 0.200 |
Why?
|
| Rats | 12 | 2004 | 5300 | 0.200 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 138 | 0.200 |
Why?
|
| Dietary Supplements | 3 | 2018 | 331 | 0.200 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2001 | 42 | 0.200 |
Why?
|
| Pharmacists | 2 | 2015 | 125 | 0.200 |
Why?
|
| Glucose Tolerance Test | 4 | 2012 | 75 | 0.200 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 438 | 0.200 |
Why?
|
| Ketanserin | 2 | 1994 | 7 | 0.200 |
Why?
|
| Sweden | 1 | 2021 | 21 | 0.200 |
Why?
|
| Cell Movement | 2 | 2001 | 630 | 0.190 |
Why?
|
| Splanchnic Circulation | 1 | 2001 | 11 | 0.190 |
Why?
|
| Minority Groups | 2 | 2015 | 196 | 0.190 |
Why?
|
| Venules | 1 | 2001 | 8 | 0.190 |
Why?
|
| State Health Plans | 1 | 2001 | 13 | 0.190 |
Why?
|
| Brain Ischemia | 3 | 2022 | 665 | 0.190 |
Why?
|
| Ireland | 2 | 2020 | 13 | 0.190 |
Why?
|
| Neurotransmitter Agents | 2 | 1991 | 102 | 0.190 |
Why?
|
| Reference Values | 5 | 2005 | 579 | 0.190 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1997 | 72 | 0.190 |
Why?
|
| Taurine | 1 | 2001 | 51 | 0.190 |
Why?
|
| Aorta | 3 | 2009 | 316 | 0.190 |
Why?
|
| Leukocytes | 1 | 2001 | 99 | 0.190 |
Why?
|
| Dietary Carbohydrates | 1 | 2000 | 27 | 0.180 |
Why?
|
| Italy | 1 | 2020 | 36 | 0.180 |
Why?
|
| Prognosis | 3 | 2019 | 2093 | 0.180 |
Why?
|
| Blood Flow Velocity | 3 | 2014 | 172 | 0.180 |
Why?
|
| Walking | 2 | 2015 | 241 | 0.180 |
Why?
|
| Elasticity | 3 | 2009 | 103 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 90 | 0.180 |
Why?
|
| Secondary Prevention | 3 | 2016 | 291 | 0.180 |
Why?
|
| Frail Elderly | 1 | 2020 | 31 | 0.180 |
Why?
|
| Diet Records | 1 | 2020 | 14 | 0.180 |
Why?
|
| Meals | 1 | 2020 | 14 | 0.180 |
Why?
|
| Hyperhidrosis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Axilla | 1 | 2020 | 36 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2015 | 374 | 0.180 |
Why?
|
| Energy Intake | 2 | 2020 | 123 | 0.180 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 546 | 0.170 |
Why?
|
| Ramipril | 2 | 2010 | 10 | 0.170 |
Why?
|
| India | 1 | 2019 | 41 | 0.170 |
Why?
|
| Educational Status | 1 | 2020 | 273 | 0.170 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2020 | 31 | 0.170 |
Why?
|
| Self Report | 1 | 2021 | 370 | 0.170 |
Why?
|
| Accountable Care Organizations | 1 | 2019 | 7 | 0.170 |
Why?
|
| Fumarates | 2 | 2010 | 28 | 0.170 |
Why?
|
| Potassium, Dietary | 2 | 2009 | 3 | 0.170 |
Why?
|
| Platelet Activation | 2 | 2022 | 24 | 0.170 |
Why?
|
| Nebivolol | 1 | 2018 | 6 | 0.160 |
Why?
|
| Amides | 2 | 2010 | 86 | 0.160 |
Why?
|
| Risk | 6 | 2012 | 563 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 104 | 0.160 |
Why?
|
| Atenolol | 1 | 2018 | 20 | 0.160 |
Why?
|
| Preventive Health Services | 2 | 2017 | 86 | 0.160 |
Why?
|
| Smoking | 5 | 2018 | 1449 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 455 | 0.160 |
Why?
|
| Fruit | 2 | 2009 | 86 | 0.160 |
Why?
|
| Vegetables | 2 | 2009 | 76 | 0.160 |
Why?
|
| Pharmaceutic Aids | 1 | 1998 | 7 | 0.160 |
Why?
|
| Cardiac Output | 4 | 2009 | 133 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 2 | 1996 | 163 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 621 | 0.160 |
Why?
|
| Drug Costs | 2 | 2017 | 87 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2018 | 73 | 0.150 |
Why?
|
| Program Evaluation | 5 | 2011 | 502 | 0.150 |
Why?
|
| Smokers | 1 | 2020 | 198 | 0.150 |
Why?
|
| Social Marketing | 2 | 2015 | 33 | 0.150 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 334 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 107 | 0.150 |
Why?
|
| Algorithms | 3 | 2009 | 1195 | 0.150 |
Why?
|
| Perception | 1 | 2018 | 189 | 0.150 |
Why?
|
| Glucose | 2 | 1996 | 307 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2017 | 31 | 0.150 |
Why?
|
| Placebos | 5 | 2008 | 195 | 0.140 |
Why?
|
| Reflex | 2 | 1996 | 21 | 0.140 |
Why?
|
| Numbers Needed To Treat | 1 | 2016 | 4 | 0.140 |
Why?
|
| Healthy People Programs | 1 | 2016 | 13 | 0.140 |
Why?
|
| Relaxation Therapy | 1 | 1996 | 19 | 0.140 |
Why?
|
| Carbenoxolone | 1 | 1996 | 4 | 0.140 |
Why?
|
| Medicaid | 2 | 2018 | 301 | 0.140 |
Why?
|
| Electrolytes | 2 | 2009 | 47 | 0.140 |
Why?
|
| Angiotensin I | 1 | 2016 | 24 | 0.140 |
Why?
|
| Mitosis | 1 | 1996 | 76 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 1998 | 499 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2016 | 108 | 0.140 |
Why?
|
| Meditation | 1 | 1996 | 33 | 0.130 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 31 | 0.130 |
Why?
|
| Carbohydrates | 1 | 2016 | 57 | 0.130 |
Why?
|
| Office Visits | 3 | 2011 | 83 | 0.130 |
Why?
|
| Overweight | 3 | 2013 | 186 | 0.130 |
Why?
|
| Musculoskeletal Diseases | 1 | 1996 | 45 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 517 | 0.130 |
Why?
|
| Cells, Cultured | 6 | 2004 | 2673 | 0.130 |
Why?
|
| Fish Oils | 1 | 1994 | 21 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 126 | 0.120 |
Why?
|
| Safety | 1 | 2015 | 145 | 0.120 |
Why?
|
| Models, Biological | 2 | 1997 | 981 | 0.120 |
Why?
|
| Anthropometry | 4 | 2016 | 64 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 148 | 0.120 |
Why?
|
| Enalapril | 3 | 1996 | 86 | 0.120 |
Why?
|
| Parents | 2 | 2016 | 309 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2015 | 248 | 0.120 |
Why?
|
| Hydralazine | 1 | 2014 | 12 | 0.120 |
Why?
|
| Dietary Fats | 4 | 2003 | 103 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2014 | 13 | 0.120 |
Why?
|
| Sympatholytics | 1 | 1994 | 11 | 0.120 |
Why?
|
| Arteries | 4 | 2005 | 108 | 0.120 |
Why?
|
| Stress, Psychological | 2 | 2021 | 824 | 0.120 |
Why?
|
| Organizational Culture | 1 | 2014 | 59 | 0.120 |
Why?
|
| Epithelial Sodium Channel Blockers | 1 | 2013 | 3 | 0.120 |
Why?
|
| Serotonin Antagonists | 1 | 1994 | 31 | 0.120 |
Why?
|
| Amiloride | 1 | 2013 | 22 | 0.120 |
Why?
|
| Lisinopril | 1 | 1993 | 16 | 0.120 |
Why?
|
| Hospitals, Teaching | 2 | 2013 | 65 | 0.120 |
Why?
|
| Nurses | 1 | 2014 | 53 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2006 | 1615 | 0.120 |
Why?
|
| North Carolina | 2 | 2006 | 224 | 0.110 |
Why?
|
| Vasomotor System | 2 | 2001 | 5 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1998 | 107 | 0.110 |
Why?
|
| Medulla Oblongata | 2 | 2005 | 19 | 0.110 |
Why?
|
| Ischemia | 2 | 2011 | 229 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 37 | 0.110 |
Why?
|
| Dipyridamole | 3 | 2022 | 26 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 274 | 0.110 |
Why?
|
| Child | 7 | 2014 | 6401 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 1996 | 328 | 0.110 |
Why?
|
| Platelet Aggregation | 2 | 1992 | 127 | 0.110 |
Why?
|
| Hospitals | 1 | 2015 | 265 | 0.110 |
Why?
|
| Cerebral Veins | 1 | 1992 | 6 | 0.100 |
Why?
|
| Acute Disease | 3 | 2003 | 658 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 711 | 0.100 |
Why?
|
| Thrombin | 1 | 2012 | 117 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 326 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 296 | 0.100 |
Why?
|
| Stents | 2 | 2016 | 657 | 0.100 |
Why?
|
| Calcium, Dietary | 2 | 2009 | 35 | 0.100 |
Why?
|
| Cerebral Arteries | 1 | 1992 | 50 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2012 | 71 | 0.100 |
Why?
|
| Statistics as Topic | 2 | 2012 | 219 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 82 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2012 | 110 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2012 | 85 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2015 | 714 | 0.100 |
Why?
|
| Infant, Low Birth Weight | 3 | 2001 | 84 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2011 | 49 | 0.100 |
Why?
|
| Popliteal Artery | 1 | 2011 | 40 | 0.100 |
Why?
|
| Limb Salvage | 1 | 2011 | 39 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1993 | 239 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 3 | 2019 | 99 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 50 | 0.100 |
Why?
|
| Erythrocytes | 2 | 1988 | 137 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2013 | 369 | 0.100 |
Why?
|
| Foot | 1 | 2011 | 66 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 1998 | 791 | 0.100 |
Why?
|
| Staff Development | 1 | 2011 | 35 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 174 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2014 | 3187 | 0.100 |
Why?
|
| Mechanoreceptors | 3 | 1987 | 11 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 279 | 0.090 |
Why?
|
| Patient Compliance | 3 | 2003 | 402 | 0.090 |
Why?
|
| Mothers | 1 | 2012 | 172 | 0.090 |
Why?
|
| Social Responsibility | 1 | 2010 | 39 | 0.090 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2012 | 134 | 0.090 |
Why?
|
| Electrocardiography | 1 | 1993 | 601 | 0.090 |
Why?
|
| Stearic Acids | 2 | 2001 | 6 | 0.090 |
Why?
|
| Breast Feeding | 1 | 2012 | 159 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 16 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 161 | 0.090 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1989 | 4 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 364 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2011 | 186 | 0.090 |
Why?
|
| Heart | 4 | 1990 | 850 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2010 | 169 | 0.090 |
Why?
|
| Compliance | 2 | 2003 | 26 | 0.090 |
Why?
|
| Drug Synergism | 2 | 2001 | 260 | 0.080 |
Why?
|
| Magnesium | 1 | 2009 | 110 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2014 | 1054 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 135 | 0.080 |
Why?
|
| Cardiomegaly | 1 | 1989 | 213 | 0.080 |
Why?
|
| Inpatients | 1 | 2010 | 208 | 0.080 |
Why?
|
| Psyllium | 1 | 2008 | 3 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2001 | 1040 | 0.080 |
Why?
|
| Health Personnel | 1 | 2011 | 286 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 1989 | 383 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2077 | 0.080 |
Why?
|
| Acetylcholine | 2 | 1997 | 64 | 0.080 |
Why?
|
| Aging | 2 | 1997 | 911 | 0.080 |
Why?
|
| Cardiovascular System | 2 | 1989 | 85 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2010 | 384 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2001 | 356 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 442 | 0.070 |
Why?
|
| Cell Count | 2 | 1998 | 248 | 0.070 |
Why?
|
| Valsartan | 3 | 2012 | 99 | 0.070 |
Why?
|
| Alcoholism | 2 | 2006 | 1109 | 0.070 |
Why?
|
| Middle Cerebral Artery | 2 | 2019 | 57 | 0.070 |
Why?
|
| Drug Interactions | 2 | 1998 | 289 | 0.070 |
Why?
|
| Women's Health | 2 | 2007 | 148 | 0.070 |
Why?
|
| Acetylcysteine | 2 | 2001 | 296 | 0.070 |
Why?
|
| Uric Acid | 2 | 2000 | 37 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 780 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2008 | 222 | 0.070 |
Why?
|
| Georgia | 1 | 2006 | 161 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2007 | 260 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 83 | 0.070 |
Why?
|
| Inflammation | 3 | 2014 | 1030 | 0.070 |
Why?
|
| Global Health | 1 | 2006 | 135 | 0.070 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 34 | 0.070 |
Why?
|
| Urban Health | 1 | 2006 | 49 | 0.070 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 807 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 659 | 0.070 |
Why?
|
| Linoleic Acid | 2 | 2004 | 13 | 0.070 |
Why?
|
| Knowledge | 1 | 2005 | 18 | 0.070 |
Why?
|
| Rural Health | 1 | 2006 | 66 | 0.070 |
Why?
|
| Homeostasis | 3 | 1997 | 291 | 0.070 |
Why?
|
| Alcoholic Intoxication | 1 | 2006 | 61 | 0.060 |
Why?
|
| Hyperinsulinism | 2 | 1997 | 23 | 0.060 |
Why?
|
| Habits | 1 | 2005 | 14 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2001 | 2083 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 188 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 255 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2005 | 310 | 0.060 |
Why?
|
| Vasopressins | 1 | 1984 | 33 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 488 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 91 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2010 | 596 | 0.060 |
Why?
|
| Students | 1 | 2007 | 233 | 0.060 |
Why?
|
| Heart Atria | 2 | 2004 | 206 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 349 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1549 | 0.060 |
Why?
|
| Birth Weight | 2 | 2003 | 186 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 1985 | 94 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2017 | 489 | 0.060 |
Why?
|
| Marital Status | 2 | 2015 | 65 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 275 | 0.060 |
Why?
|
| Medical Audit | 1 | 2003 | 44 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 242 | 0.060 |
Why?
|
| Data Collection | 1 | 2005 | 420 | 0.060 |
Why?
|
| Catecholamines | 3 | 1992 | 73 | 0.060 |
Why?
|
| Hungary | 2 | 2013 | 10 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2003 | 586 | 0.060 |
Why?
|
| Guanidines | 3 | 1990 | 32 | 0.060 |
Why?
|
| Hematocrit | 2 | 1995 | 70 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2005 | 307 | 0.060 |
Why?
|
| Medical Records | 1 | 2004 | 121 | 0.060 |
Why?
|
| Spain | 2 | 2013 | 34 | 0.060 |
Why?
|
| Diabetic Nephropathies | 1 | 2004 | 161 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 80 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2003 | 424 | 0.060 |
Why?
|
| England | 2 | 2013 | 64 | 0.060 |
Why?
|
| Germany | 2 | 2013 | 67 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 281 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2003 | 66 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2003 | 100 | 0.050 |
Why?
|
| Leptin | 1 | 2003 | 80 | 0.050 |
Why?
|
| Ticlopidine | 2 | 2014 | 118 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 204 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 306 | 0.050 |
Why?
|
| Biological Transport | 2 | 1996 | 210 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 66 | 0.050 |
Why?
|
| Calcium | 2 | 2001 | 929 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 448 | 0.050 |
Why?
|
| Models, Cardiovascular | 2 | 2015 | 133 | 0.050 |
Why?
|
| Appetite Depressants | 1 | 2021 | 11 | 0.050 |
Why?
|
| Thromboxane B2 | 1 | 2001 | 108 | 0.050 |
Why?
|
| Phentermine | 1 | 2021 | 17 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2016 | 411 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 235 | 0.050 |
Why?
|
| Hormones | 2 | 1991 | 42 | 0.050 |
Why?
|
| Maleimides | 1 | 2001 | 15 | 0.050 |
Why?
|
| Microscopy, Video | 1 | 2001 | 27 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 182 | 0.050 |
Why?
|
| Amlodipine | 2 | 2011 | 31 | 0.050 |
Why?
|
| Androstadienes | 1 | 2001 | 41 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2003 | 248 | 0.050 |
Why?
|
| Antioxidants | 1 | 2003 | 304 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2000 | 58 | 0.050 |
Why?
|
| Physical Exertion | 3 | 1986 | 75 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2020 | 6 | 0.040 |
Why?
|
| Indoles | 1 | 2001 | 146 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2006 | 652 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 396 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 503 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2001 | 324 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2001 | 223 | 0.040 |
Why?
|
| Quality of Life | 1 | 2008 | 1515 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2004 | 1329 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 481 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2001 | 447 | 0.040 |
Why?
|
| Social Class | 2 | 2015 | 127 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 1465 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 1979 | 43 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 349 | 0.040 |
Why?
|
| Mitogens | 1 | 1998 | 45 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1979 | 68 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2001 | 368 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 1998 | 8 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 1998 | 34 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 1998 | 39 | 0.040 |
Why?
|
| Health Education | 1 | 2001 | 279 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 48 | 0.040 |
Why?
|
| Arteriosclerosis | 2 | 1991 | 137 | 0.040 |
Why?
|
| Patient Admission | 1 | 1999 | 99 | 0.040 |
Why?
|
| Lipoproteins | 1 | 1999 | 161 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1998 | 31 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 147 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 168 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 1997 | 20 | 0.040 |
Why?
|
| Methacholine Chloride | 1 | 1997 | 20 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1998 | 80 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 140 | 0.040 |
Why?
|
| Natriuresis | 1 | 1997 | 13 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 134 | 0.040 |
Why?
|
| Biomechanical Phenomena | 2 | 1989 | 368 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 248 | 0.040 |
Why?
|
| Isradipine | 1 | 1997 | 3 | 0.040 |
Why?
|
| Basal Metabolism | 1 | 1997 | 22 | 0.040 |
Why?
|
| Contraceptives, Oral | 1 | 1997 | 28 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 1999 | 384 | 0.040 |
Why?
|
| Cell Division | 1 | 1998 | 541 | 0.040 |
Why?
|
| Thymidine | 1 | 1996 | 32 | 0.040 |
Why?
|
| Posture | 4 | 1984 | 107 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2006 | 2455 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1851 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 1988 | 134 | 0.040 |
Why?
|
| Lipolysis | 1 | 1996 | 13 | 0.030 |
Why?
|
| Thigh | 1 | 1996 | 27 | 0.030 |
Why?
|
| Constriction | 1 | 1996 | 37 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 230 | 0.030 |
Why?
|
| Lung | 3 | 1987 | 849 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 74 | 0.030 |
Why?
|
| Health Policy | 1 | 1998 | 221 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 249 | 0.030 |
Why?
|
| District of Columbia | 1 | 2015 | 23 | 0.030 |
Why?
|
| Family Health | 1 | 2016 | 83 | 0.030 |
Why?
|
| Marketing | 1 | 2015 | 26 | 0.030 |
Why?
|
| Abdomen | 1 | 1995 | 80 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1996 | 765 | 0.030 |
Why?
|
| Epinephrine | 1 | 1995 | 103 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1995 | 139 | 0.030 |
Why?
|
| Rabbits | 1 | 1995 | 509 | 0.030 |
Why?
|
| Cattle | 1 | 1995 | 475 | 0.030 |
Why?
|
| Orthopedics | 1 | 1996 | 88 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2014 | 53 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2014 | 55 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1996 | 211 | 0.030 |
Why?
|
| Infant | 3 | 2012 | 2891 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Caffeine | 2 | 1985 | 81 | 0.030 |
Why?
|
| Nifedipine | 1 | 1993 | 40 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2013 | 34 | 0.030 |
Why?
|
| Tetraspanin 30 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 1994 | 84 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 215 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2013 | 21 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 43 | 0.030 |
Why?
|
| P-Selectin | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 475 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2013 | 31 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2013 | 112 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 467 | 0.030 |
Why?
|
| Nephrology | 1 | 2013 | 43 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 507 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1993 | 100 | 0.030 |
Why?
|
| Finland | 1 | 2012 | 13 | 0.030 |
Why?
|
| Weaning | 1 | 2012 | 12 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2013 | 228 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 5 | 0.030 |
Why?
|
| Schools | 1 | 2013 | 156 | 0.030 |
Why?
|
| Thrombosis | 1 | 2013 | 218 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2012 | 21 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 105 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2013 | 141 | 0.030 |
Why?
|
| Zona Glomerulosa | 2 | 2004 | 2 | 0.030 |
Why?
|
| Space-Time Clustering | 1 | 1992 | 15 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.030 |
Why?
|
| Verapamil | 1 | 1991 | 30 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1991 | 42 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 236 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 521 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 209 | 0.020 |
Why?
|
| Lithium | 2 | 1988 | 76 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 127 | 0.020 |
Why?
|
| Plasma Volume | 1 | 1991 | 5 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 1991 | 9 | 0.020 |
Why?
|
| Protestantism | 1 | 2011 | 9 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2011 | 40 | 0.020 |
Why?
|
| Physical Fitness | 2 | 1997 | 117 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 1992 | 189 | 0.020 |
Why?
|
| Minority Health | 1 | 2010 | 14 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 191 | 0.020 |
Why?
|
| Creatinine | 1 | 1991 | 243 | 0.020 |
Why?
|
| Professional Practice | 1 | 2010 | 47 | 0.020 |
Why?
|
| Police | 1 | 2010 | 34 | 0.020 |
Why?
|
| Crime | 1 | 2010 | 53 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1991 | 381 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1989 | 68 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 778 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 146 | 0.020 |
Why?
|
| Phentolamine | 1 | 1989 | 8 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1989 | 153 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 54 | 0.020 |
Why?
|
| Models, Neurological | 1 | 1989 | 136 | 0.020 |
Why?
|
| Anemia, Pernicious | 1 | 1968 | 11 | 0.020 |
Why?
|
| Growth | 1 | 1968 | 17 | 0.020 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1968 | 17 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1968 | 21 | 0.020 |
Why?
|
| Body Water | 1 | 1988 | 35 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1988 | 86 | 0.020 |
Why?
|
| Fibrinolytic Agents | 2 | 2003 | 377 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 1985 | 805 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2008 | 87 | 0.020 |
Why?
|
| Body Constitution | 2 | 1998 | 24 | 0.020 |
Why?
|
| Antiporters | 1 | 1987 | 5 | 0.020 |
Why?
|
| Injections | 1 | 1987 | 119 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 1968 | 114 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 64 | 0.020 |
Why?
|
| Calorimetry, Indirect | 2 | 1997 | 12 | 0.020 |
Why?
|
| Clonidine | 2 | 2000 | 66 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 330 | 0.020 |
Why?
|
| Aerobiosis | 1 | 1986 | 19 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2006 | 37 | 0.020 |
Why?
|
| Continuity of Patient Care | 2 | 1998 | 170 | 0.020 |
Why?
|
| Anger | 1 | 1986 | 47 | 0.020 |
Why?
|
| Geography | 1 | 2006 | 80 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2006 | 27 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 120 | 0.020 |
Why?
|
| Yohimbine | 1 | 1985 | 41 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 114 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 193 | 0.020 |
Why?
|
| Transferrin | 1 | 2006 | 94 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 1995 | 164 | 0.020 |
Why?
|
| Blood | 1 | 1984 | 40 | 0.020 |
Why?
|
| Pupil | 1 | 1985 | 51 | 0.020 |
Why?
|
| International Cooperation | 1 | 2005 | 88 | 0.020 |
Why?
|
| Arm | 1 | 1985 | 59 | 0.020 |
Why?
|
| Hypertrophy | 1 | 1985 | 89 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1984 | 78 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 2222 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1987 | 597 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2005 | 182 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2003 | 17 | 0.010 |
Why?
|
| Liver | 2 | 1999 | 1118 | 0.010 |
Why?
|
| Anxiety | 1 | 1986 | 422 | 0.010 |
Why?
|
| Dipeptides | 1 | 1983 | 89 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 730 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 334 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 361 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 737 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 33 | 0.010 |
Why?
|
| Causality | 1 | 2000 | 81 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 242 | 0.010 |
Why?
|
| Lauric Acids | 1 | 1999 | 3 | 0.010 |
Why?
|
| Labor Unions | 1 | 1979 | 3 | 0.010 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1979 | 29 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1999 | 56 | 0.010 |
Why?
|
| Education | 1 | 1999 | 83 | 0.010 |
Why?
|
| Ethanol | 1 | 2005 | 892 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1998 | 46 | 0.010 |
Why?
|
| Volunteers | 1 | 1998 | 30 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1998 | 191 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2000 | 880 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 150 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 241 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 1997 | 64 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1998 | 222 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 782 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1999 | 419 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1998 | 295 | 0.010 |
Why?
|
| Weight Gain | 1 | 1997 | 135 | 0.010 |
Why?
|
| Gene Expression | 1 | 1998 | 770 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 129 | 0.010 |
Why?
|
| Plethysmography | 1 | 1995 | 17 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1995 | 24 | 0.010 |
Why?
|
| Calorimetry | 1 | 1995 | 21 | 0.010 |
Why?
|
| beta-Thromboglobulin | 1 | 1995 | 7 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1996 | 138 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1995 | 29 | 0.010 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 1995 | 43 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 231 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 329 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 1752 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1663 | 0.010 |
Why?
|
| Leg | 1 | 1995 | 191 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 902 | 0.010 |
Why?
|
| Prazosin | 1 | 1990 | 10 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1979 | 1172 | 0.010 |
Why?
|
| Propranolol | 1 | 1989 | 102 | 0.010 |
Why?
|
| Eating | 1 | 1990 | 119 | 0.010 |
Why?
|
| Anemia, Macrocytic | 1 | 1968 | 4 | 0.010 |
Why?
|
| Intrinsic Factor | 1 | 1968 | 3 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 219 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1968 | 18 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1968 | 32 | 0.010 |
Why?
|
| Diet Therapy | 1 | 1968 | 22 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1968 | 31 | 0.000 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 102 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1968 | 86 | 0.000 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 1987 | 10 | 0.000 |
Why?
|
| Echocardiography | 1 | 1990 | 515 | 0.000 |
Why?
|
| Venous Pressure | 1 | 1986 | 7 | 0.000 |
Why?
|
| Mice | 1 | 1998 | 8474 | 0.000 |
Why?
|
| Psychological Tests | 1 | 1986 | 96 | 0.000 |
Why?
|
| Arousal | 1 | 1986 | 168 | 0.000 |
Why?
|
| Reflex, Stretch | 1 | 1983 | 12 | 0.000 |
Why?
|